B cell infusion from a family donor for ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This early-stage trial tests if infusing a family member's B cells (a type of immune cell) can slow ALS progression. It is for people with ALS who have a half-matched relative willing to donate cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed ALS diagnosis (probable or definite by El Escorial criteria).
- You must be between 18 and 70 years old.
- Your breathing function (FVC) must be above 65% of expected.
- Your ALS functional score (ALSFRS-R) must be above 30.
- You need a family donor (like a parent, child, or sibling) who is a half-match and willing to donate their B cells.
- You must not have a history of certain infections, cancer, or unstable heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a transplant of special cells from donated umbilical cord blood can help slow or improve symptoms of ALS (amyotrophic lateral sclerosis, also called Lou Gehrig's disease). The cells may help repair nerve damage and reduce disease progression.
This study is looking for biological markers in the blood that can help monitor how ALS progresses and potentially detect it earlier. By participating, you may help improve future diagnosis and care for ALS patients.
This trial tests RAPA-501, a treatment made using your own immune cells, to slow progression of ALS. It may help by changing how your immune system responds in ALS.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This study is testing whether injecting special cells (called Q-Cells) into the spinal cord is safe for people with ALS. It's an early-stage trial, so the main goal is to check safety, but it might help slow down the disease in the future.
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
Hear when a new ALS - Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.